Syneos Health Inc
F:8IN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Syneos Health Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
S
|
Syneos Health Inc
F:8IN
|
4.1B EUR |
6%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
14%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
230.9B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166.6B USD |
19%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.2B CHF |
15%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
41.7B USD |
21%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD |
14%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
283.4B CNY |
30%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
37%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
30B USD |
28%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
21B EUR |
17%
|
Syneos Health Inc
Glance View
Syneos Health Inc., a formidable player in the biopharmaceutical realm, makes its mark as a dynamic integrated biopharmaceutical solutions organization. The company skillfully blends clinical development and commercial services to support pharma, biotech, and healthcare companies in navigating the complexities of bringing new therapies to market. With deep roots in clinical trials and commercialization, Syneos leverages its unique position of being involved in both the development and the market launch of new drugs—a dual focus that gives them a competitive advantage. Their business model thrives on partnerships, built on offering tailored solutions that bridge the gap between clinical insights and commercial acumen, allowing their clients to accelerate the journey from innovative ideas to patient impact. At the heart of Syneos Health's profitability are its two main segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions arm is committed to orchestrating the myriad stages of the drug development process, from early-phase trials to regulatory approval. This involves meticulously managing trials, patient recruitment, regulatory submissions, and data science applications to ensure efficacy and safety are satisfactorily demonstrated. Meanwhile, the Commercial Solutions division strategically steers approved products into the market with precision, leveraging an array of marketing, consulting, communications, and operations expertise. This holistic suite of services not only ensures a seamless transition from lab to market but also optimizes the commercial potential of their clients’ innovations, ensuring both regulatory and market success. Through these interwoven facets of clinical and commercial services, Syneos Health carves out a distinct role in the lifecycle of therapeutics development and delivery.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Syneos Health Inc's most recent financial statements, the company has Operating Margin of 6.3%.